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ttp://dx.doi.org/10.1016/j.jmoldx.2013.11.005The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders of ineffective he-
matopoiesis that characteristically demonstrate peripheral blood cytopenia, bone marrow hyper-
cellularity, and morphologically deﬁned dysplasia of one or more hematopoietic lineages. Classical
metaphase cytogenetics and judicious use of ﬂuorescence in situ hybridization play central roles in the
contemporary diagnosis and classiﬁcation of MDS. An abundance of recent molecular studies are
beginning to delineate additional genetic and epigenetic aberrations associated with these disorders.
These alterations affect diagnosis, prognosis, and therapy, and with this understanding classiﬁcation
systems are evolving from a primarily hematological and morphological basis toward a multifactorial
appreciation that includes histomorphology, metaphase cytogenetics, and directed molecular studies.
In the present health-care environment, it is critical to develop a cost-effective, efﬁcient testing
strategy that maximizes the diagnostic potential of even limited specimens. Here, we brieﬂy review the
classical genetic approach to MDS, outline exciting new advances in the molecular understanding of this
heterogeneous group of hematological neoplasms, and discuss how these advances are driving the
evolution of classiﬁcation and prognostic systems. Rapidly growing understanding of the genetic basis
of MDS holds much promise for testing, and here we provide a frame of reference for discussion of
current testing protocols and for addressing testing modalities likely to enter clinical practice in the
near future. (J Mol Diagn 2014, 16: 145e158; http://dx.doi.org/10.1016/j.jmoldx.2013.11.005)Disclosures: None declared.The myelodysplastic syndromes (MDS) are hematopoietic
stem cell neoplasms that are typically associated with
peripheral blood cytopenias (despite bone marrow hyper-
cellularity) due to ineffective hematopoiesis and character-
istically demonstrate morphologically deﬁned dysplasia of
one or more lineages. In essence, despite quantitatively
increased hematopoiesis, peripheral cytopenias are present
because the increased hematopoiesis is qualitatively defec-
tive. MDS typically affect the elderly; 85% of cases are
diagnosed after the age of 60 years, and the median age atstigative Pathology
.diagnosis is 76 years,1 although MDS are also recognized as
causes of bone marrow failure in the pediatric setting.2 Once
thought of as almost invariably leading to the development
of an acute leukemia (as reﬂected in their historic designa-
tion as preleukemic syndromes), our understanding of these
diseases as a distinct group of disorders has evolved with the
recognition that a majority of cases never progress to
acute myeloid leukemia (AML). Nonetheless, there is
Nybakken and Baggstill signiﬁcant morbidity and mortality due to progressive
cytopenias.
The FrencheAmericaneBritish classiﬁcation was one of
the ﬁrst schemas for classiﬁcation.3 The categories were based
purely on morphological grounds, with blast and monocyte
counts, and the presence or absence of ring sideroblasts being
the deﬁning features. The International Prognostic Scoring
System (IPSS) demonstrated the independent predictive value
of cytogenetics and multiple cytopenias.4 The fourth edition of
theWorld Health Organization monograph subclassiﬁes MDS
into risk categories with variable rates of mortality and pro-
gression to acute leukemia, typically AML.2 These include a
low-risk category, for refractory cytopenia with unilineage
dysplasia (RCUD), isolated 5q syndrome, and refractory
anemia with ring sideroblasts (RARS); an intermediate-risk
category, for refractory cytopenia with multilineage
dysplasia (RCMD)with or without ring sideroblasts, as well as
refractory anemia with excess blasts-1 (RAEB-1)]; and a high-
risk category, for refractory anemia with excess blasts-2
(RAEB-2) (Table 1).2 These diagnoses are not purely hema-
tologically and morphologically based; rather, integration with
cytogenetic ﬁndings is integral to the accurate diagnosis andTable 1 2008 World Health Organization MDS Classiﬁcation and Criter
Classiﬁcation Blood ﬁndings
Refractory cytopenia with unilineage
dysplasia (RCUD)
Refractory anemia (RA), refractory
neutropenia (RN), refractory
thrombocytopenia (RT)
Unicytopenia or bicytopenia
No or rare blasts (<1%)
Refractory anemia with ring sideroblasts
(RARS)
Anemia
No blasts
Refractory cytopenia with multilineage
dysplasia (RCMD)
Cytopenia(s)
No or rare blasts (<1%)
No Auer rods
<1  109/L monocytes
Refractory anemia with excess blasts-1
(RAEB-1)
Cytopenia(s)
<5% blasts
No Auer rods
<1  109/L monocytes
Refractory anemia with excess blasts-2
(RAEB-2)
Cytopenia(s)
5%e19% blasts
Auer rods 
<1  109/L monocytes
Myelodysplastic syndrome e
unclassiﬁed (MDS-U)
Cytopenias
1% blasts
MDS associated with isolated del(5q) Anemia
Usually normal or increased p
No or rare blasts (<1%)
Adapted from Swerdlow et al.2
146categorization of MDS. For instance, in an appropriate clinical
and hematological setting, cytogenetic studies are necessary
(and sufﬁcient) for the diagnosis of the 5q syndrome. In
other instances, they allow a presumptive diagnosis ofMDS in
the absence of any morphological dysplasia. In addition to the
gross and microscopically detectable chromosomal deletions,
gains, and rearrangements identiﬁed by metaphase cytoge-
netics and ﬂuorescence in situ hybridization (FISH), there are a
host of submicroscopic changes, including mutations, and
epigenetic andmiRNA alterations. Although theWorld Health
Organization classiﬁcation does not currently recognize the
latter group with respect to facilitating a diagnosis of MDS (as
NPM1 and CEBPA mutations are for provisional AML sub-
types),2 their roles in diagnostics and guiding therapeutic
decisions are growing.
The molecular basis for MDS is only beginning to be
elucidated, and unifying themes remain elusive, although
epigenetic and spliceosome pathways are emerging as
frequent targets. Regardless, genetic alterations in hemato-
poietic precursors (likely including stem cells) undoubtedly
underlie the distinct natural disease course of MDS sub-
types. Thus, increased understanding of the development ofia
Bone marrow ﬁndings
Unilineage dysplasia: 10% of the cells in one
myeloid lineage
<5% blasts; <15% of erythroid precursors are
ring sideroblasts
15% of erythroid precursors are ring
sideroblasts
Erythroid dysplasia only
<5% blasts
Dysplasia in 10% of the cells in two or more
myeloid lineages
<5% blasts in marrow
No Auer rods
15% ring sideroblasts
Unilineage or multilineage dysplasia
5%e9% blasts
No Auer rods
Unilineage or multilineage dysplasia
10%e19% blasts
Auer rods 
Unequivocal dysplasia in <10% of cells in one or
more myeloid cell lines when accompanied by a
cytogenetic abnormality considered as
presumptive evidence for a diagnosis of MDS
<5% blasts
latelet count
Normal to increased megakaryocytes with
hypolobated nuclei
<5% blasts
Isolated del(5q) cytogenetic abnormality
No Auer rods
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Table 2 Tools for the Detection of Genetic Abnormalities
Technique Resolution
Requirement
for dividing
cells
Global
analysis
Detects
balanced
translocations
Identiﬁes
uniparental
disomy Primary utility
Frequency of
abnormalities
detected in
MDS
Metaphase
cytogenetics
Low Yes Yes Yes No Required in all cases w50%*
FISH Low No No Yes No Only when metaphase
cytogenetics fails
Variabley
Array CGH High No Yes No No Investigational, complementaryz w80%
SNP array High No Yes No Yes Investigational, complementaryz w80%
Next-generation
sequencing
Very high No Nox Yes Yes Investigational, complementaryz w70%{
*Approximately 80% in secondary MDS.
yDepends on panel used, will detect approximately 100% of existing lesions that are speciﬁcally sought.
zMay become a routine assay in the near future.
xClinical assays are likely to be targeted to commonly mutated genes, with whole-genome (or whole-exome or whole-transcriptome) sequencing unlikely to
assume a major role in routine evaluation.
{Includes most cases with a normal karyotype.
Molecular Analysis in MDSthe disease at a mechanistic level aids in diagnosis, in
determination of prognosis, and in the generation of novel
directed therapies for MDS. In this review, we address both
diagnostic tests in current use and assays that are under
development. We hope to aid in the crafting of a judicious
diagnostic strategy that emphasizes critical diagnostic im-
plications and potential therapeutic modalities.
Common genetic alterations in MDS occur at a several
different levels, including cytogenetic, submicroscopic,
epigenetic, and RNA, and thus require multiple testing
modalities (Table 2). A diverse group of tests have been
developed to test for molecular changes, including, for
example, mutations, miRNA, and altered methylation states.
These alterations are typically based on an initial PCR step5;
however, detailed enumeration or examination of the testing
protocols is beyond the scope of this review. Similarly,
although ﬂow cytometry is assuming an increasingly
important auxiliary role in the diagnosis of MDS,6 this
methodology falls outside the scope of this review.Metaphase Cytogenetics
Conventional karyotyping performed on metaphase cells
(generally with Giemsa stain, to allow G-banding interpre-
tation) enables a coarse but very useful genome-wide sur-
vey. Typically, the G-banding evaluation of 20 metaphase
cells reveals most large translocations, gains, and deletions.
When interpreted in the context of clinical history, hema-
tological ﬁndings, and histopathological features, the con-
ventional karyotype is central to the diagnosis and accurate
classiﬁcation of MDS and essential for prognostication.
At present, in fact, the karyotype remains the most critical
factor in deﬁning the prognosis of MDS. Karyotypic ab-
normalities are detected by metaphase chromosomal anal-
ysis in approximately 50% of all cases of de novoMDS, and
are even more frequent among patients with secondaryThe Journal of Molecular Diagnostics - jmd.amjpathol.orgMDS (approximately 80%).7 If, however, the MDS is sec-
ondary to DNA-damaging chemotherapy and/or radio-
therapy for a previous neoplasm, then the speciﬁc diagnosis
of MDS no longer pertains; such cases are currently
designated by World Health Organization as therapy-related
myeloid neoplasms, which also includes AMLs that may
develop in that context.
Karyotypic abnormalities in MDS range from character-
istic abnormalities (eg, monosomy 5 or monosomy 7) to
nonspeciﬁc alterations commonly found in many different
myeloid malignancies (eg, trisomy 8). Translocations,
although mainstays for diagnosis or prognosis for most
other hematological neoplasms, appear to play a surpris-
ingly minor role in MDS. Partial or complete loss of chro-
mosomes is most commonly observed in MDS, followed by
partial or complete gains.
The most common MDS abnormality is the interstitial
deletion of chromosome 5 (5q), found in approximately
15% of cases,8 with del(7q)/monosomy 7 (approximately
10%) and trisomy 8 (approximately 10%) being somewhat
less common (Figure 1).8 In addition to these changes, a
number of other recurrent alterations occur in MDS. Some
of these allow a presumptive diagnosis of MDS in the
absence of morphological dysplasia, including 5q,
del(7q)/monosomy 7, del(13q)/monosomy 13; del(17p)/
monosomy 17/isochromosome 17q, del(11q), del(12p),
t(12p) (ie, translocation involving 12p), del(9q); or
idic(X)(q13).8 These presumptive diagnoses require chronic
cytopenias and, when present with fewer than 1% blasts in
the peripheral blood and fewer than 5% in the bone marrow,
are categorized as myelodysplastic syndrome, unclassiﬁ-
able. These patients require close monitoring and evaluation
for development into a more speciﬁc MDS type. In the
absence of other alterations, the commonly observed tri-
somy 8, del(20q), and loss of chromosome Y are not pre-
sumptive evidence of MDS, because of their relative
nonspeciﬁcity (ie, these alterations occur also in myeloid147
Complex: 3 abnormalities 2.1% Complex: >3 abnormalities 7.0%
Any other single 
or double
12.5%
Normal
55.1%
+8
4.7%
del(5q)
6.5%
Double with -7/del (7q) 1.2%
Double with del (5q) 1.6%
+19 0.4%
i(17q) 0.4%
inv(3)/t(3q)/del(3q) 0.4%
del(7q) 0.5%
del(11q) 0.7%
-7 1.6%
del(20q) 1.7%
-Y 2.2%
del(12q) 0.6%
Figure 1 Distribution of cytogenetic ﬁndings in myelodysplastic syndromes. Based on data from Table 2 in Schanz et al.9
Nybakken and Baggneoplasms other than MDS). This is not to discount their
importance, however, because nonspeciﬁc ﬁndings may still
affect the prognosis. The presence of three or more cyto-
genetic abnormalities (complex cytogenetics) portends an
adverse outcome. Complex karyotypes are found in 10% to
20% of patients with primary MDS at the time of diagnosis7
and in approximately 45% of patients with therapy-related
myeloid neoplasms.10
Translocations in MDS can be disease deﬁning, despite
their relative rarity. Among the more common of these rare
rearrangements are t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1),
t(1;3)(p36.3;q21.2), t(2;11)(p21;q23), inv(3)(q21q26.2), and
t(6;9)(p23;q34). It should be noted that inv(3) and t(6;9) are
also recurrent rearrangements seen in cases of AML that often
demonstrate dysplasia. For these two rearrangements, how-
ever, the current World Health Organization classiﬁcation
does not mandate a diagnosis of AML [as it does for t(8;21),
t(15;17), and inv(16)] regardless of blast count; instead, close
clinical monitoring is advised.2 It is important to keep in mind
that cytogenetic abnormalities inMDS are not likely to remain
static, but typically accumulate with disease progression.
The mechanistic connection between the numerical
changes or rearrangements and the development of MDS is
unclear. Dissection of the 5q syndrome has provided the
most detailed understanding, with thoroughly explored
minimally deleted regions. Extensive searches for mutated
genes on the remaining unaffected 5q arm failed to identify
a candidate gene. Further studies have explored the148possibility of haploinsufﬁciency, and RPS14, which encodes
a component of the 40S ribosomal subunit, is one of the
leading candidates at present.11 Disruption of ribosomal
biogenesis perturbs p53 signaling, leading to increased
apoptosis, which is a feature of low-grade MDS.12 RNAi-
reduced RPS14 is associated with relatively isolated inef-
fective erythropoiesis.11 Furthermore, restoration of RPS14
expression in a patient-derived cell line can recover normal
erythropoiesis.11 The miRNA gene MIR145 is also located
in the commonly deleted region, and haploinsufﬁciency of
this gene leads to increased expression of FLI1, resulting in
thrombocytosis,13 sometimes a feature of MDS.
Examination of del(7q)/monosomy 7 for critical genetic
regions has begun to yield results. EZH2 mutations, often
with acquired uniparental disomy, are frequently found in
patients with MDS (and other hematological neoplasms),
but this gene is not found in the minimally deleted region of
7q, and the mutations do not occur in conjunction with
deletions.14 Although three commonly deleted regions in 7q
have been identiﬁed, mutations have not been found in the
complementary chromosome.15 As a result, as for 5q,
haploinsufﬁciency is posited as a potential mechanism.
Speciﬁc genes, however, remain to be identiﬁed. Interest-
ingly, patients with isolated trisomy 8 often have strong,
sustained responses to immunomodulatory therapy, sug-
gesting a different mechanism behind the development of
MDS in these cases. Much effort has been directed to isolate
the critical regions, but to date they remain unclear.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Molecular Analysis in MDSIn addition to their prominent role in diagnosis and
classiﬁcation, cytogenetic abnormalities also have crucial
prognostic implications. Most prognostic systems, including
the International Prognostic Scoring System (IPSS)4 and the
World Health Organization classiﬁcationebased Prognostic
Scoring System (WPSS),16 have cytogenetics (in particular
complexity) as an element in determining risk. Since the
original IPSS was published, further data demonstrated that
cytogenetics were underweighted.9,17 Accordingly, the
recently published IPSS-R (revised IPSS) has increased
the importance of cytogenetics, and divided cytogenetic
abnormalities into ﬁve different prognostic groupings
(Table 3).9,18 The new cytogenetic groupings are now
weighted more strongly than even the blast count. Each
increased class away from “very good” cytogenetics adds a
point to the overall score, culminating with 4 for “very
poor.” Blast count, even at 10% to 19%, is limited to a score
of 3. Y and del(11q) are the only cytogenetic abnormal-
ities that do not worsen an IPSS-R score.
A further cytogenetic wrinkle is that of the monosomal
karyotype (deﬁned as two or more autosomal monosomies or
one autosomal monosomy in the presence of a structural
abnormality).19 These lesions, originally described in AML,
have been suggested to have important prognostic implica-
tions in MDS as well.20e22 However, the monosomal kar-
yotype is not directly addressed by the IPSS-R and has a
somewhat subjective deﬁnition, with the strict cytogenetic
deﬁnition seemingly only loosely applied in most reports. For
example, it may be difﬁcult to completely exclude the pres-
ence of additional material from a lost chromosome, either on
a marker chromosome or added to another seemingly normal
chromosome.23 Although one study showed an independent
effect of the monosomal karyotype, another study did
not.21,22 Rather, the monosomal karyotype appears to be
highly correlated with genomic instability, which is associ-
ated with a complex karyotype. The poor prognosis appears
to be due to the number of additional chromosomal defects
that deﬁne a complex karyotype.24 Further randomized
studies will be necessary to deﬁnitively demonstrate whether
the monosomal karyotype has an independent effect.
It is thus clear that karyotyping is critical, not only for
every patient with a new diagnosis of MDS, but also forTable 3 Prognostically Important Karyotypic Abnormalities in de Novo
Prognostic
subgroup Cytogenetic abnormality
Very good Y, del(11q)
Good Normal, del(5q), del(12q), del(20q); double including de
Intermediate Del(7q), þ8, þ19, i(17q); any other single or double in
Poor 7, inv(3) or t(3q) or del(3q); double including 7 or
(3 abnormalities)
Very poor Complex (>3 abnormalities)
Based on IPSS-R.9,18
NR, not reached; OS, overall survival.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgpatients with MDS in the differential diagnosis, including
those with persistent, unexplained cytopenias. These
patients, even in the absence of morphologically identiﬁ-
able dysplasia, may still represent incipient cases of MDS
(should an appropriate cytogenetic abnormality be found).
Thus, obtaining a baseline cytogenetic proﬁle is extremely
important in all patients with suspected MDS. Furthermore,
aberrations frequently accumulate and, when they do,
portend adverse prognosis and progression. Therefore,
although appropriate testing intervals are not well delin-
eated, monitoring patients with a conventional karyotype is
recommended.25,26FISH
FISH is a molecular method for determining cytogenetic
abnormalities, including gains, losses, and translocations.
The use of sequence-speciﬁc probes obviates the need for
dividing (metaphase) cells and allows testing on interphase
cells, including formalin-ﬁxed, parafﬁn-embedded tissue.
Additionally, the assay allows detection of small or cryptic
abnormalities that are invisible to metaphase karyotyping.
Given the biased representation of cytogenetic abnor-
malities in MDS (eg, high percentages of cases involve
chromosomes 5, 7, 8, and 20), some have speculated that
FISH could even replace metaphase cytogenetics as the
primary method for determining classiﬁcation and prog-
nosis. Initial, smaller studies generally indicated a role for
FISH in facilitating a diagnosis of MDS.27,28 More recently,
however, larger studies have demonstrated that FISH detects
only approximately 70% of the abnormalities detected by
cytogenetics.29 This is to be expected, given the directed
nature of the assay and the heterogeneous nature of MDS,
both cytogenetically and clinically. Thus, this directed
approach could signiﬁcantly under-represent the risk of
progression in cases that, according to FISH studies alone,
fall short of complex cytogenetics.
Furthermore, larger studies have demonstrated that FISH
has only limited ability to detect abnormalities that are un-
detectable by metaphase cytogenetics with at least 20 cells
analyzed.29e36 Six studies with more than 75 patients haveMDS
Frequency
Median
survival
(years)
Progression
to AML
(years)
Hazard
ratio
OS AML
4% 5.4 NR 0.7 0.4
l(5q) 72% 4.8 9.4 1.0 1.0
dependent clones 13% 2.7 2.5 1.5 1.8
del(7q); complex 4% 1.5 1.7 2.3 2.3
7% 0.7 0.7 3.8 3.6
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Table 4 Common Molecular Alterations in MDS
Gene
symbol Locus Gene name Mutation and effect
Prognostic
implication Protein function Frequency
SF3B1 2q33.1 Splicing factor 3b, subunit 1,
155 kDa
Missense; possible dominant
negative or gain of function
Unclear;
possibly
positive
RNA-splicing factor 3b subunit
1, part of U2
w20%*
TET2 4q24 Tet methylcytosine
deoxygenase 2
Nonsense/indel mutations
throughout; nonfunctional.
Missense in catalytic
domain; nonfunctional
Unclear;
possibly
positive
Alpha ketoglutarate-dependent
dioxygenase
w20%
RUNX1 21q22.3 Runt-related transcription
factor 1
Missense in the runt domain;
dominant negative.
Nonsense/indel/splice site
distal; nonfunctional
Negative Member of transcription factor
protein complex
w15%
ASXL1 20q11 Additional sex combs like 1
(Drosophila)
Nonsense/indel; dominant
negative or activation
Negative Chromatin-binding protein w10%e20%
SRSF2 17q25.1 Serine/arginine-rich splicing
factor 2
Missense; possible dominant
negative or gain of function
Negative Serine/arginine-rich pre-mRNA
splicing factor
w12%
TP53 17p13.1 Tumor protein p53 Missense/indel; nonfunctional Negative Multiple: DNA damage repair,
apoptosis
w10%y
NRAS 1p13.2 Neuroblastoma RAS viral
(v-ras) oncogene homolog
Missense; activation None GTPase signal transducer
controlling cell growth
w10%
DNMT3A 2p23 DNA (cytosine-5-)-
methyltransferase 3 alpha
Missense; dominant negative Negative DNA methyltransferase w8%
U2AF1z 21q22.3 U2 small nuclear RNA auxiliary
factor 1
Missense; possibly dominant
negative or gain of function
None U2 small nuclear RNA splicing
factor
w7%
EZH2 7q35wq36 Enhancer of zeste homolog 2
(Drosophila)
Missense in the SET domain;
nonfunctional. Nonsense/
indel; nonfunctional
Negative Histone-methylating protein w6%
SETBP1 18q21.1 SET binding protein 1 Missense in SKI-homologous
domain; impairs degradation
Negative Binds SET, unclear function w2%e5%
KMT2Ax 11q23 Lysine (K)-specific
methyltransferase 2A
Partial tandem duplications;
activation
Negative Transcriptional coactivator w4%
CEBPA 19q13.1 CCAAT/enhancer-binding
protein (C/EBP), alpha
Indel/nonsense; nonfunctional None bZIP transcription factor w1%e4%
ZRSR2{ Xp22.1 zinc finger (CCCH type),
RNA-binding motif and
serine/arginine rich 2
Nonsense/indel/splice sites;
nonfunctional
None Zinc finger RNA binding
associated with U2
w3%
FLT3 13q12 Fms-related tyrosine kinase 3 Insertion; activation. Missense
kinase domain; activation
Unclear FMS-like receptor tyrosine
kinase, class III
w2%
ETV6 12p13 Ets variant 6 Missense/indel; nonfunctional Negative ETS family transcription factor w2%
IDH1 2q33.3 Isocitrate dehydrogenase 1
(NADPþ), soluble
Missense; altered function Negative NADP-dependent isocitrate
dehydrogenase
w2%
IDH2 15q26.1 Isocitrate dehydrogenase 2
(NADPþ), mitochondrial
Missense; altered function None NADP-dependent isocitrate
dehydrogenase
w2%
NPM1 5q35.1 Nucleophosmin (nucleolar
phosphoprotein B23,
numatrin)
Indel; cytoplasmic localization,
p53 inactivation
None Phosphoprotein, nuclear and
cytoplasmic
w2%
KIT 4q11wq12 V-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene
homolog
Missense; activation Unclear Receptor tyrosine kinase w1%
GNAS 20q13.3 GNAS complex locus Missense; activation None G protein alpha subunit w1%
PTPN11 12q24 Protein tyrosine phosphatase,
non-receptor type 11
Missense; activation None Protein tyrosine phosphatase w1%
CBL 11q23.3 Cbl proto-oncogene, E3
ubiquitin protein ligase
Missense; inactivation,
possibly dominant negative
None Tyrosine kinase-associated
ubiquitin ligase
w1%
*60% to 80% in refractory anemia with ring sideroblasts.
y20% in secondary MDS.
zPreviously U2AFBP, “U2(RNU2) small nuclear RNA auxiliary factor 1,” “U2(RNU2) small nuclear RNA auxiliary factor binding protein.” Alias: RN, RNU2AF1,
U2AF35.
xPreviously MLL, “myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog),” “myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila).” Alias: ALL-1, CXXC7, HRX, HTRX1, MLL1A, TRX1.
{Previously U2AFIL2, “U2 small nuclear RNA auxiliary factor 1-like 2,” “U2(RNU2) small nuclear RNA auxiliary factor 1-like 2.” Alias: U2AF1-RS2, URP.
Nybakken and Bagg
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Molecular Analysis in MDSexamined this issue, and ﬁve of the studies had concordant
results.29e32,35,37 Rigolin et al37 provided the sole outlier; in
their study, approximately 20% of patients with a
completely normal cytogenetics assay had additional ﬁnd-
ings revealed by FISH; in the remaining studies,29e32,35 the
false-negative rate for conventional cytogenetics was
2.8%. Both Costa et al31 and Douet-Guilbert et al35 failed
to ﬁnd any false negatives (in 77 and 158 patients, respec-
tively). In their study of 102 patients with normal cytoge-
netics, Pitchford et al32 uncovered only one additional
ﬁnding by FISH that could be attributed to the patient’s
monoclonal B-cell lymphocytosis. Jiang et al30 reported a
false-negative rate of 2.8% (in 134 patients), and Coleman
et al29 a false-negative rate of 2.7% (in 222 patients).
Although comparisons are complicated by the different
FISH panels used, in studies including >1100 MDS patients
with normal cytogenetics total, FISH detected a cytoge-
netic abnormality that was not detected by metaphase
analysis in fewer than 3% of cases in all but one study,
and had 90% agreement with metaphase cytogenetics.
The preponderance of evidence suggests that the false-
negative rate for conventional cytogenetics is very low.
Given the high rates of agreement between conventional
cytogenetics and FISH, parallel testing is not warranted
and the additional cost is unnecessary. The primary utility
of FISH should be in the setting of inadequate meta-
phase yield (<20 metaphase cells) by conventional
cytogenetics.29,30,32,33,35,38CGH
Comparative genomic hybridization (CGH), another mo-
lecular approach, is a useful tool for assaying DNA copy
number variation in a sample. Although it is more analyti-
cally sensitive than metaphase cytogenetics, CGH is unable
to detect balanced rearrangements, because these do not
typically change the copy number.
Initial studies involving low-resolution CGH demonstrated
similar results to those obtained with metaphase cytoge-
netics.39 The introduction of higher-resolution methodologies
have shown increased sensitivity to cryptic changes.40,41 In a
study of 107 patients who had conventional cytogenetics
performed, CGH revealed cryptic ﬁndings in 39%, often
affecting regions tightly associated with MDS, such as loss of
5q31.2 and 7q22.1.42 Further recurrent alterations affected
genetic loci involved in myeloid malignancies, such as
4q24(TET2) and 21q22.3(RUNX1).41 Additional regions with
losses and gains included genes associated with red cell dis-
orders (EPB42/15q15wq21 and SPTA1/1q21), Chédiake
Higashi syndrome (LYST/1q42.1wq42.2), hemophagocytic
syndrome (RAB27/15q15wq21.1 and MCFD2/2p21),
hematopoietic development (MBP/18q23), myeloid malig-
nancy [MECOM(EVI1)/3q26.2], cytochrome P450 enzymes
(CYP51A1/7q21.2), ribosomal genes (RRP1B/21q22.3 and
RRP1/21q22.3), and portions of the snRNA-processingThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcomplex (INTS8/8p22.1).41 Although not all deletions are of
clear signiﬁcance,42 the ﬁndings of cryptic chromosomal du-
plications and losses in patients with a normal metaphase
karyotype are of prognostic utility.40,41 A study of patients with
low-risk MDS demonstrated a similar prognostic value for
CGH; recurrent alterations in this study included common
MDS abnormalities involving 5q, 7 and 7q, 8, 11q, and 20q, as
well as alterations in other regions (including 2p and 2q, 4p and
4q, 6p, 10q, 14q, 15q, 17q, 19p and 19q, and 22q).40 Because
array CGH (aCGH) has been demonstrated to increase prog-
nostic value beyond that of metaphase cytogenetics, it is likely
to be of use as a complement to conventional cytogenetics.
SNP Arrays
Single-nucleotide polymorphism (SNP) arrays, with the
ability to sensitively detect loss of heterozygosity in tumors,
also appear to be a useful addition to metaphase cytoge-
netics by capturing additional cryptic gains or losses. Use of
SNP arrays results in the discovery of with chromosomal
abnormalities in 75% of patients, compared with 50% of
patients for metaphase cytogenetics alone. Most impor-
tantly, these cryptic changes are adverse prognostic in-
dicators, compared with patients without SNP-identiﬁable
alterations and with normal cytogenetic proﬁles.43 This
prognostic utility, however, is not completely independent
from the already well-described alterations in the IPSS. In
diagnostic MDS specimens, SNP arrays are starting to
become a complementary method for conventional cytoge-
netics, with their own prognostic import.44 Furthermore,
they may play a role in classiﬁcation. SNP array has been
used to distinguish hypocellular MDS from aplastic anemia,
and thus it may be used in a diagnostic role to delineate
these entities.45 SNP analysis cannot, however, detect
balanced chromosomal translocations, and it may miss some
minor clones. These limitations hinder its use as a stand-
alone test, but may still allow an adjunct role in the diag-
nosis of MDS.
No direct comparison of aCGH and SNP arrays in MDS
has yet been published. Different platforms have, however,
been compared for their ability to detect genomic variations
in a number of settings.46,47 Results vary, depending on the
methodology used. Furthermore, as new platforms and
higher-density systems are developed, it not clear whether
any preferred strategy will emerge for detecting copy
number variation in MDS. Recently, high concordance was
noted between bone marrow and peripheral blood SNP
testing, suggesting that peripheral blood specimens may be
sufﬁcient both for initial characterization and for subsequent
monitoring of the genetic status of MDS patients.48
Mutations
Single-gene molecular alterations in MDS are currently being
elucidated at a rapid pace. Approximately 70% of MDS151
Nybakken and Baggpatients have detectable mutations, but no speciﬁc mutation is
present in more than approximately 20% of patients with
MDS (Table 4).49 In fact, the vast majority of mutations are
of low incidence.50 Unsurprisingly, cases of secondary MDS
are more likely to have mutations than cases of de novo
MDS, and they may display quite different frequencies of
individual mutations.51 A wide variety of mutations have
been identiﬁed, including TET2, RUNX1, TP53, NRAS, and
ASXL1, and less commonly CBL and EZH2 (Table 4). Other
mutations frequently described in AML have been found in
MDS, including ATRX,52 NPM1,53 IDH1,54 IDH2,54
CEBPA,55 KMT2A (previously MLL),56 PTPN11,53,57
FLT3,53 SETBP1,58,59 and KIT.60 These mutations, however,
are found at lower rates in MDS than AML, and generally are
of uncertain signiﬁcance. Mutations of IDH1, IDH2, FLT3,
and KIT are associated with more advanced disease and with
progression to AML, and may better represent evolution to
AML rather than the MDS per se.
Recently, a large study of MDS mutations conﬁrmed
these ﬁndings, and suggested molecular testing for muta-
tions in TP53, EZH2, ETV6, RUNX1, and ASXL1, because
these demonstrate independent prognostic value.61 In
particular, the report advocated using the presence of a
mutation in any of these genes as an independent adverse
prognostic factor.61 Furthermore, distinct clinical subgroups
were associated with particular mutations, and it is specu-
lated that such mutations may, in part, explain interpatient
variability in MDS. Previously undescribed mutations were
found in two genes, ETV6 and GNAS.61 These commonly
mutated genes, although encoding proteins involved in
many cellular processes, do suggest critical pathways, often
involved with protein synthesis (Figure 2). DNA methyl-
ation and histone modiﬁcation enzymes, both key mecha-
nisms for epigenetic control (see below), are frequent
targets. Many other mutations affect genes encoding pro-
teins that are transcription factors or tyrosine kinases, likely
playing roles in either blocking maturation/differentiation or
increasing proliferation, respectively.
More recent studies have demonstrated a critical role for the
RNA spliceosome in the pathogenesis ofMDS.62 Collectively,
approximately 45% of MDS patients have mutations in
U2AF1 (alias U2AF35),63 ZRSR2,64 SRSF2, or SF3B1.65
These mutations commonly affect 30 splice-site recognition
and are generally mutually exclusive.62 Furthermore, MDS
subtypes have differential mutation rates, with a particularly
strong association (approximately 80%) between SF3B1 mu-
tations and MDS with ring sideroblasts.66 In a mouse model,
haploinsufﬁciency for SF3B1 leads to ring sideroblast for-
mation in a mouse model.67 Furthermore, these mutations
sorted with respect to other common mutations. RUNX1 and
IDH1 mutations were commonly found together with SRSF2
mutations, and ASXL1 and DNMT3A mutations were seen in
patients with U2AF1 mutations.64 Interestingly, ribosomal
alterations, including alterations of RNA machinery, have
been implicated in both the development of 5q syndrome
and various bone marrow failure syndromes, including152ShwachmaneBodianeDiamond syndrome and Diamonde
Blackfan anemia, that may be associatedwith the development
of MDS. For now, the relationship between these newly
described mutations and these bonemarrow failure syndromes
remains uncertain.
Mutations in mitochondrial DNA have been also associ-
ated with MDS, including mutations resulting in decreased
expression of the iron transporter ABCB7. Mutations of
ABCB7 have been associated with inherited ring sideroblast
formation.68 Mitochondrial mutations are found in nearly
60% of patients and are correlated with age and advanced
disease. Phenotype correlations, however, are lacking.69 The
alterations in mitochondrial DNA and iron transport in
particular are unsurprising, given the ﬁnding of mitochon-
drial iron deposition in ring sideroblasts. However, with no
clear prognostic or therapeutic implications of mitochondrial
mutations, no testing strategies are currently directed at them.
Testing for speciﬁc genomic DNA mutations is not
currently common practice for MDS, although recent ad-
vances demonstrate a prognostic and therapeutic advantage
to testing. Further studies demonstrating clinical beneﬁt are
required before such testing is incorporated into the standard
of care. At a minimum, such testing may facilitate rendering
a diagnosis in otherwise diagnostically challenging cases.
As with SNP arrays, peripheral blood may be as useful a
specimen as bone marrow for targeted next-generation
sequencing (high-throughput sequencing) at diagnosis and
for monitoring.48
The advent of next-generation sequencing raises additional
considerations for mutational analysis. Unsupervised global
sequencing is able to detect mutations in the majority of cases
of MDS, and could also be used to detect balanced trans-
locations, gains and losses, and uniparental disomy. This
powerful method will undoubtedly alter how we look for
mutations in the future. At present, however, the ability to
analyze the data, especially with low-frequency mutations or
noncoding mutations, is an issue for routine clinical settings.
Furthermore, although next-generation sequencing is
increasingly facile in detecting fusions and numeric changes,
not all cytogenetic aberrations are detectable, and therefore
these technologies cannot yet replace the karyotype. Never-
theless, the detection of key mutations could be accomplished
through targeted testing of small groups of genes (or regions
thereof), with perhaps a total of as few as 5 to 20 genes being
required for contemporary diagnosis.
Epigenetic Changes
Epigenetic changes result in altered gene expression in the
absence of DNA sequencemutations. The twomost prominent
mechanisms in MDS, DNA methylation and histone acetyla-
tion and methylation, also play roles in physiological hema-
topoiesis; however, these mechanisms have been implicated in
carcinogenesis in general, often through blocking expression
of tumor suppressor genes. MDS is associated on a genomic
level with a global reduction in methylation. This overalljmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Mutations that affect the fundamental pathway of transcription, RNA splicing, and ribosomal biogenesis. DNA in a steady state of transcriptional
regulation (middle) is subject to methylation (top) and histone modiﬁcation (bottom). DNMTs methylate DNA, reducing transcription; mutation of DNMT3A
(one of the genes encoding a DMNT) affects this process. TET2 mediates a step in the opposite process, removing DNA methylations; mutations of the TET2
gene lead to a loss of this demethylation function. IDH1/2 mutations result in altered enzymatic function and production of 2-hydroxyglutarate, which inhibits
TET2. Histones (green balls) reduce transcription through increased binding. Histone deacetylases (HDACs) and EZH2 modify histone acetylation (red lines)
and methylation (magenta circles), resulting in increased histone avidity for DNA and reduced transcription. Mutations of EZH2 and ASXL1 lead to dysre-
gulation of histone modiﬁcation. The spliceosome processes mRNA, removing introns (blue lines); genes encoding proteins that constitute the splicing
machinery [SF3B1, U2AF1 (alias U2AF35), ZRSR2, and SRSF2] are mutated in MDS (Table 4) and may result in aberrant splicing. mRNA processing adds the 50
methyl guanine cap (tan box) and the polyalanine tail (green line). Ribosomal proteins, including RPS14(5q-syndrome), RPS19(DBA), and SBDS, play roles in
ribosomes (blue ovals), translating mRNA into protein; these ribosomal genes are targeted in 5q syndrome and in hereditary bone marrow failure syndromes
(eg, DiamondeBlackfan anemia and ShwachmaneBodianeDiamond syndrome).
Molecular Analysis in MDSreduction is uneven, however, and methylation is focally
increased around tumor suppressors and other mitogen in-
hibitors. DNA methyl transferases (DNMTs) are thought to
mediate much of the increased methylation and have therefore
become a key treatment target in MDS.
Large-scale examination of methylation status in MDS
demonstrates that 12% of analyzed genes in high-risk MDS
display promoter methylation, compared with only 6% of
genes in low-risk MDS; however, this difference is not sta-
tistically signiﬁcant. The genes identiﬁed are involved in an
array of functions, including DNA repair, cell-cycle control,
and regulation of development, differentiation, and
apoptosis. Of high-risk MDS patients, 70% had hyper-
methylation of ALOX12, GSTM1, HIC1, FZD9, and
HS3ST2.70 Furthermore, therapeutic use of DNMT inhibitors
results in global reduction in promoter methylation.71
A number of genes encoding proteins that modulate the
epigenetic status, including IDH1/2, TET2, and DNMT3A, are
mutated in myeloid malignancies. These mutations are often
mutually exclusive (eg, TET2 and IDH1/2), suggesting a
driving role in pathogenesis. Interestingly, these mutations areThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsomewhat less common in MDS than in AML, suggesting that
they are associated more with progression than with MDS per
se.72 Of the DNMT gene family, only DNMT3A is commonly
mutated in MDS.73 These mutations, although present in only
8% of patients, are thought to be early events and are associated
with progression and adverse prognosis.73 Interestingly, altered
methylation states and TET2mutations are each associatedwith
response to demethylating agents, and could potentially act as a
therapeutic markers.74
Although there are strategies for assaying methylation status
in other conditions (eg, Angelman and PradereWilli syn-
dromes), there is no current standardized clinical assay inMDS.
Although global analysis of methylation is possible, more
directed analysis is also recommended for validation ofﬁndings
in the global assessment. Three general techniques are used to
evaluate global methylation: methylation-sensitive restriction
endonucleases, methylated DNA-enrichment strategies, and
bisulﬁte conversion. Methylation-sensitive restriction endonu-
clease techniques, such as restriction landmark genomic scan-
ning (RLGS assay) or HpaII tiny fragment enrichment by
ligation-mediated PCR (HELP assay), are limited by the153
Nybakken and Baggdistribution ofmeasurable sites and are being replaced bynewer
methods. Methylated DNA-enrichment strategies use methyl
CpG-binding domain proteins to enrich the tested areas.
Bisulﬁte converts cytosine to uracil but leaves 5-methyl cyto-
sine intact; PCR then enables comparison of C/T levels and an
estimation of themethylation status. Site-directed analysis relies
on bisulﬁte-basedmethods for determination of themethylation
levels. A variety of methods can be used to measure the status,
including methylation-speciﬁc PCR, methylation-speciﬁc
melting-curve analysis, sequencing (traditional or pyrose-
quencing), or MassARRAY analysis (to transcribe the product
into RNA and then assay for methylation with mass spec-
trometry). These assays are more thoroughly discussed in a
recent review.75
miRNA Abnormalities
miRNAs (short, single-stranded RNA molecules) affect
post-transcriptional protein expression levels through the
RNA-induced silencing complex (RISC). The RISC complex
targets RNA sequences for destruction mediated by Dicer,
an endoribonuclease that recognizes double-stranded RNA.
miRNA binds complementary single-stranded RNAFigure 3 Diagnostic algorithm summarizing the genetic testing mo-
dalities that are of value in MDS. Additional studies are not currently
routinely used, but are poised to enter into routine testing in the near
future. aCGH and/or SNP mutation testing might include a targeted panel
of approximately 5 to 20 genes.
154sequences, which leads to Dicer-mediated destruction,
providing a mechanism for modulating protein expression.
miRNAs have a deﬁned role in physiological hematopoiesis,
and more recently have been implicated in MDS through the
epigenetic modiﬁcation of protein expression. Despite iden-
tiﬁed miRNA products and distinct expression levels in
controls, in patients with MDS, and in patients progressing to
AML,76 no standardized assay for clinical use has yet been
developed. Furthermore, there is little overlap among many
of the published studies.77 It would be premature to dismiss
the relevance of miRNAs in MDS, however, because they
clearly have an important role, as evidenced by the devel-
opment of MDS in a mouse model with deleted Dicer1,78 as
well as the effects of MIR145 loss in 5q alluded to above.
Genetic Lesions Affecting Therapy
In addition to their role in the determination of prognosis,
genetic ﬁndings can also play a role in determination of
appropriate therapy. By aiding the separation into high- and
low-risk groups, cytogenetic analysis can also assort patient
into different treatment regimens. Low-risk patients are
frequently treated with supportive care, including red blood
cell and platelet transfusions, or bone marrow-stimulating
agents. Higher-risk disease is more likely to be treated with
cytotoxic therapies; in fact, for some RAEB-2 cases the
treatment may be akin to that for AML. More directed ther-
apies exist for speciﬁc genetic lesions. For instance, patients
with del(5q) have high response rates to lenalidomide, a
thalidomide analog with a broad range of activities.79
Current efforts are directed toward developing genetic
markers for response to demethylating agents and other ther-
apies. Patients with TET2 mutations have much higher
response rates (82%) when treated with azacytidine than those
with wild-type TET2 (45%).80 Furthermore, high pretreatment
levels of miR29B, a miRNA that modulates DNMT expres-
sion, have been associated with a clinical response to
decitabine in pilot studies.81 Another study, however, did not
ﬁnd a statistically signiﬁcant correlation.82 Expression of
phosphoinositide-phospholipase C b1 (PLCB1) was shown to
correlate with azacytidine response in an initial study, with
reduced PLCB1 methylation correlating with a positive
response.83 These ﬁndings are preliminary, but hold promise
for personalized therapy in myelodysplastic syndromes.Conclusions
There is a rapidly increasing recognition of the importance
of genetic changes in the diagnosis, prognosis, therapy, and
classiﬁcation of MDS. This awareness has resulted in
cytogenetics becoming the most critical prognostic ﬁnding
in the IPSS-R.18 Further studies are beginning to demon-
strate the importance of single-gene mutations and of cryptic
cytogenetic alterations in the prognosis of MDS. Although
miRNA, epigenetic changes, and mitochondrial alterationsjmd.amjpathol.org - The Journal of Molecular Diagnostics
Molecular Analysis in MDSplay important roles in pathogenesis, to date there are no
available clinical tests for their evaluation. In this shifting
ﬁeld, it is important to deﬁne the most essential and cost-
effective testing strategies for diagnosing and monitoring a
patient with MDS (Figure 3).
It is clear that metaphase cytogenetics should be attempted
at diagnosis on bone marrow specimens for every patient with
MDS. Indeed, the recently published National Comprehensive
Cancer Network Clinical Practice Guidelines in Oncology for
MDS emphasize the essential role of karyotyping in the
diagnosis of MDS.84 The results are critical for classiﬁcation
and prognosis. FISH studies, although beneﬁcial in cases with
failure of metaphase cytogenetics, should probably not be
performed ab initio, because they provide little additional in-
formation in the setting of successful metaphase cytogenetics.
Preliminary studies have demonstrated utility for SNP or CGH
arrays in providing prognostic information for patients with
MDS. Although these tests are not widely available at present
and are not yet standard of care, theymay soon become critical
adjuncts to current testing methodologies. Single-gene muta-
tion studies remain investigational, although some prognostic
value has been demonstrated. Although it does not directly
assess the MDS clone, testing for underlying bone marrow
syndromes (eg, Fanconi anemia and dyskeratosis congenita) is
also warranted in patients with a family history or when MDS
presents at a young age. Targeted analysis by next-generation
sequencing of selected genes using hybrid capture is likely to
emerge as a useful clinical approach, andwe can expect further
studies of its utility in deﬁning prognosis and in identifying
therapeutic targets. It is clear, however, that such testing is
already poised to enter diagnostic testingmenus and is likely to
be incorporated into future prognostic scoring systems.Acknowledgment
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